antipyrine has been researched along with Disease Exacerbation in 16 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2." | 7.88 | Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018) |
| "We tested whether fibrotic progression in chronic hepatitis C could be predicted by liver tests, antipyrine clearance, or platelet count." | 7.72 | Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. ( Byth, K; Coverdale, SA; Crewe, E; Farrell, GC; George, J; Kench, J; Khan, MH; Liddle, C; Lin, R; Samarasinghe, DA, 2003) |
| "Edaravone treatment significantly reduced messenger RNA expressions of cytokines and matrix metalloproteinases (MMPs) in aneurysm walls (MMP-2: 1." | 5.38 | Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats. ( Hasegawa, T; Morimoto, K; Morimoto, N; Okada, K; Okita, Y; Tanaka, A; Wulan, B; Yu, J, 2012) |
| "Edaravone treatment decreased the neutrophil infiltration, the lipid membrane peroxidation, and the expression of proinflammatory cytokine interleukin-6 mRNA in the lungs after intestinal I/R compared to the I/R-treated rat lungs without edaravone treatment." | 5.33 | Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. ( Horikawa, S; Ito, K; Ozasa, H, 2005) |
| "Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2." | 3.88 | Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018) |
| "Rats receiving intracolonic administration of indomethacin develop longitudinal ulcers on the mesenteric side of the small intestine that are similar to those seen in the acute phase of Crohn's disease." | 3.74 | Microcirculatory changes in experimental mesenteric longitudinal ulcers of the small intestine in rats. ( Haruma, K; Iida, M; Koga, H; Shimizu, K, 2007) |
| "We tested whether fibrotic progression in chronic hepatitis C could be predicted by liver tests, antipyrine clearance, or platelet count." | 3.72 | Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. ( Byth, K; Coverdale, SA; Crewe, E; Farrell, GC; George, J; Kench, J; Khan, MH; Liddle, C; Lin, R; Samarasinghe, DA, 2003) |
| "Edaravone treatment significantly reduced messenger RNA expressions of cytokines and matrix metalloproteinases (MMPs) in aneurysm walls (MMP-2: 1." | 1.38 | Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats. ( Hasegawa, T; Morimoto, K; Morimoto, N; Okada, K; Okita, Y; Tanaka, A; Wulan, B; Yu, J, 2012) |
| "Edaravone treatment decreased the neutrophil infiltration, the lipid membrane peroxidation, and the expression of proinflammatory cytokine interleukin-6 mRNA in the lungs after intestinal I/R compared to the I/R-treated rat lungs without edaravone treatment." | 1.33 | Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. ( Horikawa, S; Ito, K; Ozasa, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scott, A | 1 |
| Tanahashi, N | 1 |
| Yamaguchi, T | 1 |
| Awano, H | 1 |
| Matsuda, H | 1 |
| Endepols, H | 1 |
| Mertgens, H | 1 |
| Backes, H | 1 |
| Himmelreich, U | 1 |
| Neumaier, B | 1 |
| Graf, R | 2 |
| Mies, G | 2 |
| Ikeda, K | 1 |
| Iwasaki, Y | 1 |
| Engel, DC | 1 |
| Terpolilli, NA | 1 |
| Trabold, R | 1 |
| Loch, A | 1 |
| De Zeeuw, CI | 1 |
| Weber, JT | 1 |
| Maas, AI | 1 |
| Plesnila, N | 1 |
| Woitzik, J | 1 |
| Lassel, E | 1 |
| Hecht, N | 1 |
| Schneider, UC | 1 |
| Schroeck, H | 1 |
| Vajkoczy, P | 1 |
| Yamakawa, H | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Morimoto, K | 1 |
| Hasegawa, T | 1 |
| Tanaka, A | 1 |
| Wulan, B | 1 |
| Yu, J | 1 |
| Morimoto, N | 1 |
| Okita, Y | 1 |
| Okada, K | 1 |
| Arumugam, S | 1 |
| Thandavarayan, RA | 1 |
| Veeraveedu, PT | 1 |
| Giridharan, VV | 1 |
| Soetikno, V | 1 |
| Harima, M | 1 |
| Suzuki, K | 1 |
| Nagata, M | 1 |
| Tagaki, R | 1 |
| Kodama, M | 1 |
| Watanabe, K | 1 |
| Coverdale, SA | 1 |
| Samarasinghe, DA | 1 |
| Lin, R | 1 |
| Kench, J | 1 |
| Byth, K | 1 |
| Khan, MH | 1 |
| Crewe, E | 1 |
| Liddle, C | 1 |
| George, J | 1 |
| Farrell, GC | 1 |
| Carmichael, ST | 1 |
| Tatsukawa, K | 1 |
| Katsman, D | 1 |
| Tsuyuguchi, N | 1 |
| Kornblum, HI | 1 |
| Ito, K | 1 |
| Ozasa, H | 1 |
| Horikawa, S | 1 |
| Maeda, K | 1 |
| Tatsumi, M | 1 |
| Tahara, M | 1 |
| Murata, Y | 1 |
| Kawai, H | 1 |
| Yasuda, H | 1 |
| Nishio, M | 1 |
| Matsuda, M | 1 |
| Ohyanagi, F | 1 |
| Sato, Y | 1 |
| Okumura, S | 1 |
| Tabata, D | 1 |
| Morikawa, A | 1 |
| Nakagawa, K | 1 |
| Horai, T | 1 |
| Shimizu, K | 1 |
| Koga, H | 1 |
| Iida, M | 1 |
| Haruma, K | 1 |
| Shrestha, R | 1 |
| McKinley, C | 1 |
| Showalter, R | 1 |
| Wilner, K | 1 |
| Marsano, L | 1 |
| Vivian, B | 1 |
| Everson, GT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity[NCT02268461] | 4 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
| Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or [NCT02455167] | Phase 3 | 9 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to Study stopped due to low accrual and availability of other treatment options) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome. (NCT02455167)
Timeframe: 12 Weeks
| Intervention | score on a scale (Mean) |
|---|---|
| HCV Positive Group | 7.25 |
Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome. (NCT02455167)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| HCV Positive Group | 8 |
"Number of participants who cleared Hepatitis C (HCV) after 12 weeks was collected (HCV RNA level was Not Detected." (NCT02455167)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| HCV Positive Group | 4 |
16 other studies available for antipyrine and Disease Exacerbation
| Article | Year |
|---|---|
Drug therapy: On the treatment trail for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Di | 2017 |
Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Diabetes Mellitus; Disability Evaluation; Disea | 2018 |
Longitudinal assessment of infarct progression, brain metabolism and behavior following anterior cerebral artery occlusion in rats.
Topics: Animals; Anterior Cerebral Artery; Antipyrine; Autoradiography; Brain; Brain Infarction; Cerebrovasc | 2015 |
Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Astrocytes; Disease Models, Animal; Disease Prog | 2015 |
Changes of cerebral blood flow during the secondary expansion of a cortical contusion assessed by 14C-iodoantipyrine autoradiography in mice using a non-invasive protocol.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Autoradiography; Biomarkers; Brain; Br | 2008 |
Ischemia independent lesion evolution during focal stroke in rats.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Autoradiography; | 2009 |
Anterior spinal artery as a collateral channel in patients with acute bilateral vertebral artery occlusions. Two case reports.
Topics: Acute Disease; Aged; Antipyrine; Arginine; Brain Stem; Cerebellum; Cerebral Revascularization; Cereb | 2009 |
Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antipyrine; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apop | 2012 |
Involvement of AMPK and MAPK signaling during the progression of experimental autoimmune myocarditis in rats and its blockade using a novel antioxidant.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antipyrine; Autoimmune Diseases; Disease Models, Anim | 2012 |
Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Antiviral Agents; Biopsy; Disease | 2003 |
Evolution of diaschisis in a focal stroke model.
Topics: Animals; Antipyrine; Autoradiography; Blood Flow Velocity; Carbon Radioisotopes; Cerebrovascular Cir | 2004 |
Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat.
Topics: Animals; Antipyrine; Disease Progression; Edaravone; Interleukin-6; Intestines; Ischemia; Lung; Male | 2005 |
[A case of stroke-like episode of MELAS of which progressive spread would be prevented by edaravone].
Topics: Adult; Antipyrine; Brain; Disease Progression; Edaravone; Female; Free Radical Scavengers; Humans; M | 2005 |
Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Com | 2005 |
Microcirculatory changes in experimental mesenteric longitudinal ulcers of the small intestine in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Cytokines; Disease Models | 2007 |
Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis.
Topics: Administration, Oral; Adult; Aged; Antipyrine; Caffeine; Cholic Acid; Cholic Acids; Disease Progress | 1997 |